<DOC>
	<DOC>NCT01664143</DOC>
	<brief_summary>This single-center, randomized, double-blind, placebo-controlled study will evaluate the safety, pharmacokinetics and pharmacodynamics of RO5508887 in healthy volunteers. Volunteers will receive multiple-ascending doses of RO5508887 or matching placebo. The anticipated time on study treatment is 14 days.</brief_summary>
	<brief_title>A Single-Center Study of RO5508887 in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Adult healthy volunteers, &gt;/=18 years of age Body mass index (BMI) between 18 and 30 kg/m2 inclusive Use of adequate contraception methods or surgically sterile Evidence of active or chronic disease Regular consumption of drugs of abuse Regular smoker (&gt;5 cigarettes per day) Infection with human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C (HCV) History of significant allergic reactions Abnormal blood pressure Clinical significant abnormalities (e.g., cardiovascular, laboratory values)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>